Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
National Center for Research Resources (NCRR)
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00004776CT.gov Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Topiramate for Lennox-Gastaut Syndrome | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lennox-Gastaut Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Topiramate (this asset) | National Center for Research Resources (NCRR) | P3 | BB · 64 |
| gwp42003-p | Jazz Pharmaceuticals | P4 | BBB |
| Rufinamide | Eisai Co., Ltd. | P3 | BB |
| Benzeneethanamine, N-Ethyl-?-Methyl-4-(Trifluoromethyl)-, Hydrochloride, (±)- | University of Chicago | P3 | BB |
| Bexicaserin | Longboard Pharmaceuticals | P2 | BB |
| zx008 | Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. | P3 | BB |
| Melatonin | Institution de Lavigny | P4 | BB |
| Carisbamate | SK Life Science, Inc. | P3 | BB |
| Soticlestat | Takeda | P3 | B |
+4 more in the Lennox-Gastaut Syndrome cohort
Other indications for Topiramate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Focal Epilepsy | — | P4 | A · 80 |
| Migraine With Aura | — | P4 | BBB · 78 |
| Migraine Without Aura | — | P4 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Topiramate in Lennox-Gastaut Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/topiramate-lennox-gastaut-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →